BioScript - Important Update to the Enhertu™ (trastuzumab deruxtecan) DESTINY-Breast03 Patient Support Program

Home > Important Update to the Enhertu™ (trastuzumab deruxtecan) DESTINY-Breast03 Patient Support Program

Dear Health Care Provider,

As a healthcare provider who has previously enrolled patients in the AstraZeneca Oncology Patient Support Program (PSP) for Enhertu, we are writing to remind you of the planned closure of the free drug component for the DESTINY-Breast 03 indication on June 1, 2023.

AstraZeneca expanded the PSP for this patient population (i.e., adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least one prior anti- HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy) in June 2022 to provide eligible patients with access to free drug until June 1, 2023.

Please note that as of June 1, 2023, the free drug component of the PSP for Enhertu DESTINY-Breast03 will be closed to new enrolments. As of this date, the PSP will continue to support patients as follows:

All eligible patients enrolled in the free drug component of the PSP by end of day June 1, 2023 and started on treatment on or before July 31, 2023 will continue to receive free drug through the PSP until disease progression, or public reimbursement, whichever is earlier.

After June 1, 2023, all NEW eligible patients enrolled in the PSP will have access to educational resources, reimbursement navigation, infusion support and co-payment support toward the cost of Enhertu (up to 20%). The free drug component of the DESTINY-Breast03 PSP will no longer be available.

Should a patient be enrolled in the PSP by June 1, 2023, but not ready to start treatment by end of day July 31, 2023, the free drug component of the program will not apply.

While we work towards public access for Enhertu DESTINY-Breast03, we will continue to provide updates on the status of the PSP free drug program for eligible patients enrolled on or before June 1, 2023. Once provincial coverage is established for Enhertu DESTINY-Breast03, the PSP will notify clinicians at the time of listing and support with the transition of these patients to the publicly funded supply of Enhertu.

Please note, there are no changes at this time to the PSP offerings for the DESTINY-Breast01 or DESTINY-Breast04 indications. As a reminder, the DESTINY-Breast01 free drug component of the PSP closed May 31, 2022, and the free drug program for treatment eligible DESTINY-Breast 04 patients is scheduled to close January 31, 2024. Should there be any changes to these programs, prescribing physicians will be notified in advance.

For questions about the PSP or to enroll a patient, please call 1-877-280-6208 (Monday through Friday, 8 a.m. to 8 p.m. ET) or email enrollment@azoncologypsp.ca. If you have any questions about Enhertu, please contact your local AstraZeneca representative.

Regards,
Your Patient Care Coordinator
AstraZeneca Oncology Patient Support Program